The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
复制标题
DOI：
10.1016/j.ejca.2011.03.022
复制
发表时间：
2011-06
影响因子：
8.4
通讯作者：
Sallan, Stephen E.
中科院分区：
文献类型：
--
作者：
Vrooman, Lynda M.;Neuberg, Donna S.;Stevenson, Kristen E.;Asselin, Barbara L.;Athale, Uma H.;Clavell, Luis;Cole, Peter D.;Kelly, Kara M.;Larsen, Eric C.;Laverdiere, Caroline;Michon, Bruno;Schorin, Marshall;Schwartz, Cindy L.;Cohen, Harvey J.;Lipshultz, Steven E.;Silverman, Lewis B.;Sallan, Stephen E.
关键词：
Dexrazoxane降低了蒽环类药物相关心脏毒性的风险。在一项针对霍奇金淋巴瘤儿童的研究中，dexrazoxane的添加可能与发生第二恶性肿瘤（smn）的高风险相关，包括急性髓性白血病（AML）和骨髓增生异常综合征（MDS）。我们测定了急性淋巴细胞白血病（ALL）儿童和青少年接受右唑嗪治疗时SMNs的发生率。1996年至2010年间，Dana-Faber癌症研究所ALL联盟对新诊断的ALL儿童进行了三个连续的多中心试验。在第一阶段（1996-2000年），高风险患者被随机分配在诱导期和强化期接受阿霉素（30mg /m2/剂量，累计剂量300mg/m2），然后再接受右razoxane （300mg/m2 /剂量，10剂），或者不使用右razoxane的相同剂量的阿霉素。在随后的试验（2000-2005年和2005-2010年）中，所有高风险和极高风险患者在接受右拉唑环治疗之前都接受了阿霉素治疗。前瞻性地收集SMNs病例并汇总分析。在接受右唑嗪治疗的患者中测定SMNs的频率和5年累积发病率（CI）。553例dexrazoxane治疗患者（1996-2000年，N=101； 2000-2005年，N=196； 2005-2010年，N=256）中，方案观察到的smn数分别为0（中位随访9.6年）、0（中位随访5.2年）和1（中位随访2.1年）。唯一的SMN是一例AML，在最初诊断后2.14年发生在mll重排ALL患者身上。553例患者SMNs的总体5年CI为0.24±0.24%。在大量接受右拉唑烷作为心脏保护药物的高风险ALL儿童中，继发性AML的发生是罕见的事件。
Dexrazoxane reduces the risk of anthracycline-related cardiotoxicity. In a study of children with Hodgkin lymphoma, the addition of dexrazoxane may have been associated with a higher risk for developing second malignant neoplasms (SMNs) including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). We determined the incidence of SMNs in children and adolescents with acute lymphoblastic leukemia (ALL) who were treated with dexrazoxane. Between 1996 and 2010, the Dana-Faber Cancer Institute ALL Consortium conducted three consecutive multicenter trials for children with newly diagnosed ALL. In the first (1996–2000), high risk patients were randomly assigned to receive doxorubicin (30 mg/m2/dose, cumulative dose 300mg/m2) preceded by dexrazoxane (300 mg/m2/dose, 10 doses), or the same dose of doxorubicin without dexrazoxane, during induction and intensification phases. In subsequent trials (2000–2005 and 2005–2010), all high risk and very high risk patients received doxorubicin preceded by dexrazoxane. Cases of SMNs were collected prospectively and were pooled for analysis. The frequency and 5-year cumulative incidence (CI) of SMNs were determined for patients who had received dexrazoxane. Among 553 patients treated with dexrazoxane (1996–2000, N=101; 2000–2005, N=196; and 2005–2010, N=256), the number of SMNs observed by protocol was 0 (median follow-up 9.6 years), 0 (median follow-up 5.2 years), and 1 (median follow-up 2.1 years). The only SMN was a case of AML, which developed in a patient with MLL-rearranged ALL 2.14 years after initial diagnosis. The overall 5-year CI of SMNs for all 553 patients was 0.24 ± 0.24%. In a large population of children with high risk ALL who received dexrazoxane as a cardioprotectant drug, the occurrence of secondary AML was a rare event.
登录
查看更多内容
DOI：
10.1056/nejmoa0900386
发表时间：
2009-06-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Pui CH;Campana D;Pei D;Bowman WP;Sandlund JT;Kaste SC;Ribeiro RC;Rubnitz JE;Raimondi SC;Onciu M;Coustan-Smith E;Kun LE;Jeha S;Cheng C;Howard SC;Simmons V;Bayles A;Metzger ML;Boyett JM;Leung W;Handgretinger R;Downing JR;Evans WE;Relling MV
通讯作者：
Relling MV
影响因子：
51.1
作者：
Lipshultz, Steven E.;Scully, Rebecca E.;Lipsitz, Stuart R.;Sallan, Stephen E.;Silverman, Lewis B.;Miller, Tracie L.;Borry, Elly V.;Asselin, Barbara L.;Athale, Uma;Clavell, Luis A.;Larsen, Eric;Moghrabi, Albert;Samson, Yvan;Michon, Bruno;Schorin, Marshall A.;Cohen, Harvey J.;Neuberg, Donna S.;Orav, E. John;Colan, Steven D.
通讯作者：
Colan, Steven D.
影响因子：
45.3
作者：
Barry, Elly V.;Vrooman, Lynda M.;Silverman, Lewis B.
通讯作者：
Silverman, Lewis B.
影响因子：
11.4
作者：
Mitchell, C.;Richards, S.;Harrison, C. J.;Eden, T.
通讯作者：
Eden, T.
影响因子：
6.5
作者：
Mitchell, CD;Richards, SM;Eden, TOB
通讯作者：
Eden, TOB